Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575473 | 0.85 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2GAAKDM4E | |
| SCHEMBL6500425 | 0.82 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL13947349 | 0.82 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL483578 | 0.79 | RAB9A (0.74) | NPC1RAB9ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL13177792 | 0.77 | HDAC2 (0.63) | NPC1RAB9ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL5210637 | 0.77 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2GAAKDM4E | |
| SCHEMBL17886760 | 0.77 | ALDH1A1 (0.73) | NPC1RAB9ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL507445 | 0.77 | RAB9A (0.62) | NPC1RAB9ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL1394203 | 0.77 | RAB9A (0.74) | NPC1RAB9ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL11666172 | 0.77 | CNR1 (0.67) | NPC1RAB9ASMN1; SMN2GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | NPC1 118/4885RAB9A 1154/4885SMN1; SMN2 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.